Arkolith/Insider Trading/IKT/Form 4

Lees-Rolfe Garth

Chief Financial OfficerInhibikase Therapeutics, Inc. (IKT) · full profile →Form 4 · filed Jan 22, 2025
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
4
0 non-derivative · 4 derivative

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jan 21, 2025Disposed to issuer(D)6K—$00
Jan 21, 2025Grant(A)6K—$06K
Jan 21, 2025Disposed to issuer(D)90K—$00
Jan 21, 2025Grant(A)90K—$090K

Transaction Codes

D
Disposition to the issuer
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000950170-25-007746) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML